| Autor: |
Wu, Liangliang, Liu, Limin, Zhao, Xin, Zhou, Ming, Fu, Andie, Zhang, Yuping, Yang, Wenrui, Chen, Xiaowei, Mo, Wenjian, Wang, Caixia, Li, Yumiao, Xu, Shilin, Pan, Shiyi, Zhou, Ruiqing, Meng, Fankai, Zhang, Fengkui, Wu, Depei, Wang, Shunqing |
| Předmět: |
|
| Zdroj: |
Blood Cancer Journal; 3/6/2024, Vol. 14 Issue 1, p1-5, 5p |
| Abstrakt: |
A recent study compared the outcomes of unrelated donor hematopoietic stem cell transplantation (URD-HSCT) and immunosuppressive therapy plus eltrombopag (IST + EPAG) as first-line treatments for adults with severe aplastic anemia (SAA). The study found that URD-HSCT had improved survival outcomes compared to IST + EPAG, but there was no significant difference in hematologic response or health-related quality of life between the two treatments. The study suggests that URD-HSCT could be considered as a first-line option for adult SAA patients without a matched sibling donor. Another study focused on the outcomes of URD-HSCT in patients with non-severe aplastic anemia. The results showed successful engraftment and low rates of graft failure, acute graft-versus-host disease (aGVHD), and chronic graft-versus-host disease (cGVHD). The incidence of aGVHD was higher in patients who received a mismatched unrelated donor compared to those who received a matched unrelated donor. Overall, URD-HSCT appears to be a favorable treatment option for adult SAA patients without a matched sibling donor, but further research is needed. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink